Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1981 Mar;78(3):1873–1877. doi: 10.1073/pnas.78.3.1873

Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity.

E A Forssen, Z A Tökès
PMCID: PMC319237  PMID: 6940195

Abstract

Anionic liposomes containing doxorubicin were evaluated in mice for therapeutic potential in reducing the risks of chronic cardiotoxicity characteristic of long-term high-dose anthracycline therapy. Doxorubicin first was complexed to phosphatidylcholine and then entrapped in anionic vesicles. Quantitation of myocardial injury was accomplished through examination of thin sections of cardiac tissue by light microscopy. At treatment levels of either 20 or 40 mg/kg (total dose), mice receiving liposomal doxorubicin had toxicity scores indistinguishable from or only slightly greater than those of saline-treated controls. Similar total doses of free drug produced moderate to severe myocardial damage and yielded much higher toxicity scores. Mixture of free doxorubicin with empty liposomes did not alleviate cardiac toxicity, indicating that the drug must be entrapped within phospholipid vesicles for reduction in toxicity. The inhibition of body growth produced by free doxorubicin at both dose levels was also completely eliminated by encapsulation in liposomes. Doxorubicin liposomes were also tested for chemotherapeutic potential against L-1210 and P-388 murine leukemias. In all cases, treatment with liposomal doxorubicin produced increases in life-span greater than that observed for free drug. We conclude that anionic liposomes can function as efficacious carriers of doxorubicin. These vesicles possess improved therapeutic action as reflected by their ability to reduce cardiac toxicity, overcome growth inhibition, and increase antileukemic activity.

Full text

PDF
1873

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertazzoli C., Bellini O., Magrini U., Tosana M. G. Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1877–1883. [PubMed] [Google Scholar]
  2. Blum R. H., Carter S. K. Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med. 1974 Feb;80(2):249–259. doi: 10.7326/0003-4819-80-2-249. [DOI] [PubMed] [Google Scholar]
  3. Casazza A. M. Experimental evaluation of anthracycline analogs. Cancer Treat Rep. 1979 May;63(5):835–844. [PubMed] [Google Scholar]
  4. Duarte-Karim M., Ruysschaert J. M., Hildebrand J. Affinity of adriamycin to phospholipids. A possible explanation for cardiac mitochondrial lesions. Biochem Biophys Res Commun. 1976 Jul 26;71(2):658–663. doi: 10.1016/0006-291x(76)90838-x. [DOI] [PubMed] [Google Scholar]
  5. Forssen E. A., Tökes Z. A. In vitro and in vivo studies with adriamycin liposomes. Biochem Biophys Res Commun. 1979 Dec 28;91(4):1295–1301. doi: 10.1016/0006-291x(79)91207-5. [DOI] [PubMed] [Google Scholar]
  6. Ganapathi R., Krishan A., Wodinsky I., Zubrod C. G., Lesko L. J. Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine in vivo. Cancer Res. 1980 Mar;40(3):630–633. [PubMed] [Google Scholar]
  7. Jaenke R. S. Delayed and progressive myocardial lesions after adriamycin administration in the rabbit. Cancer Res. 1976 Aug;36(8):2958–2966. [PubMed] [Google Scholar]
  8. Juliano R. L., Stamp D. Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin. Biochem Pharmacol. 1978 Jan 1;27(1):21–27. doi: 10.1016/0006-2952(78)90252-6. [DOI] [PubMed] [Google Scholar]
  9. Lambertenghi-Deliliers G., Zanon P. L., Pozzoli E. F., Bellini O., Praga C. Ultrastructural alterations of atrial myocardium induced by adriamycin in chronically treated animals. Tumori. 1978 Feb 28;64(1):15–24. doi: 10.1177/030089167806400102. [DOI] [PubMed] [Google Scholar]
  10. Lefrak E. A., Pitha J., Rosenheim S., Gottlieb J. A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973 Aug;32(2):302–314. doi: 10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  11. Lenaz L., Page J. A. Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev. 1976 Sep;3(3):111–120. doi: 10.1016/s0305-7372(76)80018-7. [DOI] [PubMed] [Google Scholar]
  12. Mettler F. P., Young D. M., Ward J. M. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res. 1977 Aug;37(8 Pt 1):2705–2713. [PubMed] [Google Scholar]
  13. Olson H. M., Capen C. C. Subacute cardiotoxicity of adriamycin in the rat: biochemical and ultrastructural investigations. Lab Invest. 1977 Oct;37(4):386–394. [PubMed] [Google Scholar]
  14. Rahman A., Kessler A., More N., Sikic B., Rowden G., Woolley P., Schein P. S. Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res. 1980 May;40(5):1532–1537. [PubMed] [Google Scholar]
  15. Rahman Y. E., Hanson W. R., Bharucha J., Ainsworth E. J., Jaroslow B. N. Mechanisms of reduction of antitumor drug toxicity by liposome encapsulation. Ann N Y Acad Sci. 1978;308:325–342. doi: 10.1111/j.1749-6632.1978.tb22033.x. [DOI] [PubMed] [Google Scholar]
  16. Rosenoff S. H., Olson H. M., Young D. M., Bostick F., Young R. C. Adriamycin-induced cardiac damage in the mouse: a small-animal model of cardiotoxicity. J Natl Cancer Inst. 1975 Jul;55(1):191–194. doi: 10.1093/jnci/55.1.191. [DOI] [PubMed] [Google Scholar]
  17. Rustum Y. M., Dave C., Mayhew E., Papahadjopoulos D. Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia. Cancer Res. 1979 Apr;39(4):1390–1395. [PubMed] [Google Scholar]
  18. Schioppocassi G., Schwartz H. S. Membrane actions of daunorubicin in mammalian erythrocytes. Res Commun Chem Pathol Pharmacol. 1977 Nov;18(3):519–531. [PubMed] [Google Scholar]
  19. Tyrrell D. A., Heath T. D., Colley C. M., Ryman B. E. New aspects of liposomes. Biochim Biophys Acta. 1976 Dec 14;457(3-4):259–302. doi: 10.1016/0304-4157(76)90002-2. [DOI] [PubMed] [Google Scholar]
  20. Wortman J. E., Lucas V. S., Jr, Schuster E., Thiele D., Logue G. L. Sudden death during doxorubicin administration. Cancer. 1979 Nov;44(5):1588–1591. doi: 10.1002/1097-0142(197911)44:5<1588::aid-cncr2820440508>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  21. de Duve C., Trouet A., Campeneere D. D., Baurian R. Liposomes as lysosomotropic carriers. Ann N Y Acad Sci. 1978;308:226–234. doi: 10.1111/j.1749-6632.1978.tb22025.x. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES